Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21914142 | 0.85 | KMT2A (0.58) | KMT2AL3MBTL1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL13145506 | 0.81 | KMT2A (0.56) | KMT2AL3MBTL1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL25131449 | 0.80 | KMT2A (0.49) | KMT2AL3MBTL1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL8628975 | 0.79 | KMT2A (0.54) | KMT2AL3MBTL1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL30432306 | 0.79 | PKM (0.42) | KMT2AL3MBTL1ALDH1A1MEN1HPGD | |
| SCHEMBL8627524 | 0.78 | KMT2A (0.53) | KMT2AL3MBTL1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL27928357 | 0.78 | KMT2A (0.53) | KMT2AL3MBTL1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL14720965 | 0.77 | KMT2A (0.51) | KMT2AL3MBTL1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL15203323 | 0.77 | KMT2A (0.51) | KMT2AL3MBTL1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL8630249 | 0.75 | KMT2A (0.62) | KMT2AL3MBTL1ALDH1A1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | KMT2A 1976/4885L3MBTL1 2716/4885ALDH1A1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.